ibo stock: Impact BioMedical (IBO) overview
IBO (Impact BioMedical, Inc.)
ibo stock refers to the U.S. equity ticker IBO for Impact BioMedical, Inc., a micro‑cap biotechnology and healthcare holding company listed on U.S. markets. This entry summarizes the company profile, corporate timeline, securities information, business activities, financial and market characteristics, risks specific to micro‑cap biotech issuers, and primary sources for data. Readers will learn where to verify quotes and filings and how ibo stock is commonly tracked by retail investors.
Company overview
Impact BioMedical is a small-cap/ micro‑cap company focused on specialty biopharmaceuticals, consumer healthcare products and early‑stage drug discovery. Investors looking up ibo stock will typically find descriptions of the company’s role as a holding and development vehicle, its stated headquarters, and its publicly disclosed programs in press releases and SEC filings.
History and corporate timeline
A brief corporate timeline shows incorporation and subsequent name or strategy changes, any material partnership announcements, and the listing event that put ibo stock on public quotation systems. Major milestones affecting ibo stock are usually documented in company press releases and periodic reports.
Securities information
- Ticker and exchange: IBO (primary U.S. listing or quotation venue as reported in major finance portals). Retail trackers reference ibo stock on mainstream data services.
- Identifiers: ISIN and CUSIP are available in official filings and data feeds; investors should confirm identifiers in SEC filings before transacting.
As of 2026-01-26, according to Yahoo Finance and Nasdaq data portals, ibo stock is characterized by micro‑cap classification and relatively low average daily trading volume compared with large‑cap equities.
Business operations and products
Impact BioMedical has referenced early‑stage programs and consumer health initiatives in filings and corporate materials. Documents and releases outline product candidates, research efforts, or branded consumer products that may form the basis for future revenue; such program names and stages are best verified in the company’s latest filings when evaluating ibo stock.
Financials and fundamentals
Micro‑cap biotechs frequently report limited revenue and operating losses while funding research and development through financings. For current market capitalization, recent revenue, and EPS trends tied to ibo stock, check the latest quarterly reports and reliable finance portals such as Morningstar, CNBC, and Yahoo Finance.
Market performance and trading
Price volatility, a wide 52‑week range, and low liquidity are typical features when following ibo stock. Retail discussion boards and services such as StockTwits often show sentiment and trade flow for this ticker. As of 2026-01-26, sources including StockTwits and Robinhood list ibo stock alongside quote pages and community commentary.
Share structure and major holders
Outstanding shares, insider holdings and any recent financing activity are disclosed in SEC reports. Dilution risk and concentrated insider ownership can materially affect the trading dynamics of ibo stock.
Corporate governance and management
Key executives and board members are identified in the company’s proxy statements and press materials. Governance disclosures provide context investors use when assessing ibo stock’s stewardship.
Regulatory, legal and risk factors
Standard risks: clinical and regulatory setbacks, product development failure, financing and dilution risk, low liquidity and potential for extreme price swings or market‑manipulation activity—each relevant to ibo stock.
Recent developments and news
This section should list dated press releases, SEC filings (8‑K, 10‑Q, 10‑K), financings, or program updates that materially affect ibo stock. As of 2026-01-26, users should consult company press releases and filings for the most recent developments.
Comparison and peers
When comparing ibo stock to peers, use metrics such as market cap, pipeline stage, cash burn and revenue run‑rate. Peer selection typically focuses on micro‑cap biotech and consumer health firms.
Alternate/related tickers and disambiguation
A note on similarly named tickers: IBO.V is a separate listing used by another issuer on the TSX Venture Exchange (Universal Ibogaine Inc.) and is not the same as ibo stock for Impact BioMedical.
Investing considerations
This article does not provide investment advice. For trading ibo stock, perform due diligence: review SEC filings, confirm identifiers, consider liquidity and dilution risk, and verify news from primary sources. For traders seeking an on‑ramp, Bitget provides trading services and Bitget Wallet is recommended when interacting with on‑chain assets and custody solutions.
Data sources and references
As of 2026-01-26, primary sources for quotes and fundamentals on ibo stock include: Yahoo Finance, Robinhood profile pages, StockTwits feed, Morningstar, CNBC, and Nasdaq market data. For corporate disclosures, consult the company’s SEC filings and official press releases.
See also
- Biotechnology industry overview
- Micro‑cap stocks and market structure
- How to read SEC filings
- Ticker disambiguation and symbol lookup
External links
- Company investor relations and SEC EDGAR filings (search issuer filings for Impact BioMedical to access official documents)
Further exploration: review the latest SEC filings and official company releases before acting on any market information. To explore trading options, consider Bitget's platform and Bitget Wallet for custody solutions.
